Diligence memo · auto-generated · as of July 2, 2026
Temprian Therapeutics, Inc.
Temprian Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Temprian Therapeutics, Inc. operates in Pharmaceuticals, based in CHICAGO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Temprian Therapeutics, Inc. has raised $275K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $275K on 2019-01-25.
Most recent recorded round closed around 2019-01-25.
Valuation (modeled)modeled
Provath models Temprian Therapeutics, Inc. at approximately $13M (range $154K–$147M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.97× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era. Within the normal band (97% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.4 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 7% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 21% of those peers.
Closest niche peers: Elion Oncology, Inc., Cyclone Therapeutics, Inc., Sonnet Biotherapeutics, Inc., Fastball Capital Group, Llc, TamRx, LLC.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.